Sagimet's AURORA Acne Trial Set to Enroll First Patient in Q4 2026
SGMT has more than doubled off its 52-week low of $4.5.
Summary
Sagimet announced that its AURORA Phase 3 trial of denifanstat in moderate to severe acne is on track to begin patient enrollment in Q4 2026, with screening starting in October. All trial sites are identified and a CRO is engaged. The trial will enroll approximately 800 U.S. patients, including 450 adolescents, with a 12-week double-blind period and a 40-week open-label extension. This follows the FDA's IND clearance on August 13, 2026, and provides concrete operational milestones that de-risk the program's execution. The company anticipates submitting an NDA upon completion of the 12-week phase, which could position denifanstat as the first innovative oral acne treatment in over 40 years.
At the time of this announcement, SGMT was trading at $10.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $628.8M. The 52-week trading range was $4.50 to $11.15. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.